Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.

The New England journal of medicine - 19 Nov 2020

Shaw Alice T, Bauer Todd M, de Marinis Filippo, Felip Enriqueta, Goto Yasushi, Liu Geoffrey, Mazieres Julien, Kim Dong-Wan, Mok Tony, Polli Anna, Thurm Holger, Calella Anna M, Peltz Gerson, Solomon Benjamin J

Abstract excerpt

BACKGROUND: Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK), has antitumor activity in previously treated patients with ALK-positive non-small-cell lung cancer (NSCLC). The efficacy of lorlatinib, as compared with that of crizotinib, as first-line treatment for advanced ALK-positive NSCLC is unclear. METHODS: We conducted a global, randomized, phase 3 trial comparing lorlatinib with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Anaplastic Lymphoma Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Crizotinib

Share to Hyperlipidemias

Share to Lactams

Share to Lactams, Macrocyclic

Share to Pyrazoles

Share to Survival Analysis

Source

Identifiers

PMID: 33207094
DOI: 10.1056/NEJMoa2027187

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.PMID 33207094Read ↗

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to dateSemantic proximity Read ↗

Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer.Semantic proximity Read ↗

A user’s guide to lorlatinibSemantic proximity Read ↗

Alectinib for advanced ALK-positive non-small-cell lung cancer.Semantic proximity Read ↗

Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.Semantic proximity Read ↗

Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.Semantic proximity Read ↗

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung CancerSemantic proximity Read ↗

Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations.Semantic proximity Read ↗

Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.Semantic proximity Read ↗

Efficacy of lorlatinib treatment in ALK -rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance statusSemantic proximity Read ↗

Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study.Semantic proximity Read ↗

A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.